Company news

Island Pharmaceuticals Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

FDA Meeting request granted

September 18, 2025

FDA meeting request lodged for Galidesivir

August 31, 2025

Preliminary Final Report

August 28, 2025

Options exercise from existing substantial shareholder

August 11, 2025

Completion of Galidesivir transaction

July 30, 2025

Portfolio expansion achieved with acquisition of Galidesivir

July 8, 2025

Successful Phase 2 clinical trial of ISLA-101

June 12, 2025

Island completes $3.6 million placement

May 20, 2025

Quarterly Activities & Cashflow Report

April 29, 2025

Phase 2a/b clinical trial update

April 22, 2025

Completion of patient dosing in Phase 2b clinical trial

February 11, 2025

Completion of enrolment in Phase 2b arm

January 21, 2025

ISLA-101 Phase 2b clinical trial enrols first subjects

January 7, 2025

US patent granted for ISLA-101

December 10, 2024

ISLA-101 shows anti-dengue activity in Phase 2a readout

November 26, 2024

Receipt of R&D tax refund for FY2024

November 21, 2024

Clinical trial progress update

November 18, 2024

Island completes $3.5m Placement

October 3, 2024

Phase 2a PROTECT clinical trial dosed & Investor webinar

October 2, 2024

Binding LOI for proposed acquisition of Galidesivir

September 10, 2024

ISLA-101 Phase 2a/b clinical trial progresses

August 6, 2024

Non-binding term sheet signed with BioCryst

July 2, 2024

Investor Presentation

June 3, 2024

New data leads to proposed ISLA-101 Phase 2 efficiencies

June 3, 2024

Grant funding to directly support Phase 2a trial

May 7, 2024

Investor Presentation - Asia Bio Partnering

April 22, 2024

Positive data from ISLA-101 Single Ascending Dose study

April 15, 2024

Security Class Reinstatement to Quotation ILAO

April 1, 2024

Security Class Suspension from Quotation ILAO

March 26, 2024

Island Pharmaceuticals to raise $1.95 million for ISLA-101 development

February 27, 2024

Prospectus

February 25, 2024

$1.95million Fully Underwritten Rights Issue

February 25, 2024

Island investor presentation

February 6, 2024

Dosing complete in ISLA-101 SAD study

February 5, 2024

Quarterly Activity Report and Appendix 4C

January 30, 2024

Third cohort dosed in ISLA-101 Single Ascending Dose study

January 19, 2024

Approval to commence dosing 3rd cohort of ISLA-101 SAD study

December 21, 2023

R&D Tax Incentive loan facility secured with Radium Capital

December 14, 2023

Second cohort dosed in ISLA-101 Single Ascending Dose study

December 11, 2023

Island doses first cohort in ISLA-101 clinical trial

November 24, 2023

Screening commences for ISLA-101 Single Ascending Dose Study

November 12, 2023

Island receives R&D tax refund for FY2023

November 9, 2023

Island receives ethics approval for ISLA-101 study

November 6, 2023

ILA granted key Australian patent for ISLA-101

November 1, 2023

Quarterly Activity Report & Appendix 4C

October 29, 2023

ISLA-101 Single Ascending Dose study update

September 24, 2023

Island Pharmaceuticals granted key U.S. patent for ISLA-101

September 12, 2023

Appendix 4E & Annual Report

August 30, 2023

US grant funding to support ISLA-101 clinical development

July 6, 2023

Island receives FDA go-ahead for ISLA-101 program

May 15, 2023

← Newer news releases · Older news releases →

Decks

The 5 newest of 36 decks. Every deck is listed under its year.